Trial Profile

A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel/gemcitabine (Primary)
Indications Bladder cancer; Carcinoma; Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms RESCUE
Sponsors Relmada Therapeutics

Most Recent Events

02 Sep 2026 Planned End Date changed from 1 Sep 2032 to 1 Dec 2032.
02 Sep 2026 Planned primary completion date changed from 1 Sep 2029 to 1 Dec 2029.
02 Sep 2026 Planned initiation date changed from 1 Jun 2026 to 1 Feb 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com